2.50
Hdl Handle:
http://hdl.handle.net/10540/251415
Title:
RNA biomarkers in colorectal cancer
Authors:
Bustin, Stephen A.; Murphy, Jamie
Affiliation:
Anglia Ruskin University; Division of Colon and Rectal Surgery, Mayo Clinic, AZ, USA
Reference:
Bustin, S.A. and Murphy, J., 2012. RNA biomarkers in colorectal cancer. Methods, article in press.
Publisher:
Elsevier
Journal:
Methods
Issue Date:
15-Oct-2012
URI:
http://hdl.handle.net/10540/251415
DOI:
10.1016/j.ymeth.2012.10.003
PubMed ID:
23079397
Additional Links:
http://www.sciencedirect.com/science/article/pii/S1046202312002587
Abstract:
Colorectal cancer (CRC) develops and progresses through a systematic selection for (epi) genetic alterations that drive the transformation from normal colon epithelium to adenocarcinoma. These changes affect both noncoding RNAs and mRNAs and so define the clinical behaviour of cancer cells within a distinctive host genetic and environmental context. Although earlier diagnosis and more effective treatment modalities have decreased mortality from CRC, prognostic stratification and adjuvant therapy selection after surgery remain dependent on broad descriptive classifications, opportune histological markers of poor prognosis and chemotherapy efficacy data derived from diverse CRC populations. Crucially, there is significant inter- and intra-individual variability in response to, and tolerance of, chemotherapy treatments. These limitations explain the small clinical benefit of new agents studied in contemporary phase III trials. Molecular assays have the potential to address these constraints and there has been intense interest in the identification of clinically relevant molecular biomarkers. These must be easy to obtain and quantify and ideally represent steps in well-understood carcinogenic pathways or host-response mechanisms. Although some biomarkers can provide broad prognostic information based on CRC subtype (e.g. MSI status) or can somewhat predict response to targeted therapies (e.g. KRAS), no RNA-based biomarkers have entered routine clinical practice. This is due, in part, to the genetic heterogeneity of both patients and CRC. In addition, serious underlying issues with regards to study design, poor technical protocols, inadequate quality controls and inappropriate data analysis prevent successful translation of research results. Consequently, the identification of clinically relevant panels of biomarkers will depend not just on further advances in our understanding of CRC biology, but will need to be coupled with appropriate study designs and more suitable, standardised and transparent techniques.
Type:
Article
Language:
en
Keywords:
metastasis; prognosis; diagnosis; response prediction; staging; miRNA; circulating tumour cells
ISSN:
1095-9130

Full metadata record

DC FieldValue Language
dc.contributor.authorBustin, Stephen A.en_GB
dc.contributor.authorMurphy, Jamieen_GB
dc.date.accessioned2012-11-08T10:41:27Z-
dc.date.available2012-11-08T10:41:27Z-
dc.date.issued2012-10-15-
dc.identifier.citationBustin, S.A. and Murphy, J., 2012. RNA biomarkers in colorectal cancer. Methods, article in press.en_GB
dc.identifier.issn1095-9130-
dc.identifier.pmid23079397-
dc.identifier.doi10.1016/j.ymeth.2012.10.003-
dc.identifier.urihttp://hdl.handle.net/10540/251415-
dc.description.abstractColorectal cancer (CRC) develops and progresses through a systematic selection for (epi) genetic alterations that drive the transformation from normal colon epithelium to adenocarcinoma. These changes affect both noncoding RNAs and mRNAs and so define the clinical behaviour of cancer cells within a distinctive host genetic and environmental context. Although earlier diagnosis and more effective treatment modalities have decreased mortality from CRC, prognostic stratification and adjuvant therapy selection after surgery remain dependent on broad descriptive classifications, opportune histological markers of poor prognosis and chemotherapy efficacy data derived from diverse CRC populations. Crucially, there is significant inter- and intra-individual variability in response to, and tolerance of, chemotherapy treatments. These limitations explain the small clinical benefit of new agents studied in contemporary phase III trials. Molecular assays have the potential to address these constraints and there has been intense interest in the identification of clinically relevant molecular biomarkers. These must be easy to obtain and quantify and ideally represent steps in well-understood carcinogenic pathways or host-response mechanisms. Although some biomarkers can provide broad prognostic information based on CRC subtype (e.g. MSI status) or can somewhat predict response to targeted therapies (e.g. KRAS), no RNA-based biomarkers have entered routine clinical practice. This is due, in part, to the genetic heterogeneity of both patients and CRC. In addition, serious underlying issues with regards to study design, poor technical protocols, inadequate quality controls and inappropriate data analysis prevent successful translation of research results. Consequently, the identification of clinically relevant panels of biomarkers will depend not just on further advances in our understanding of CRC biology, but will need to be coupled with appropriate study designs and more suitable, standardised and transparent techniques.en_GB
dc.languageENG-
dc.language.isoenen
dc.publisherElsevieren_GB
dc.relation.urlhttp://www.sciencedirect.com/science/article/pii/S1046202312002587en_GB
dc.rightsArchived with thanks to Methods (San Diego, Calif.)en_GB
dc.subjectmetastasisen_GB
dc.subjectprognosisen_GB
dc.subjectdiagnosisen_GB
dc.subjectresponse predictionen_GB
dc.subjectstagingen_GB
dc.subjectmiRNAen_GB
dc.subjectcirculating tumour cellsen_GB
dc.titleRNA biomarkers in colorectal canceren
dc.typeArticleen
dc.contributor.departmentAnglia Ruskin Universityen_GB
dc.contributor.departmentDivision of Colon and Rectal Surgery, Mayo Clinic, AZ, USAen_GB
dc.identifier.journalMethodsen_GB

Related articles on PubMed

All Items in ARRO are protected by copyright, with all rights reserved, unless otherwise indicated.